UBS Sticks to Its Hold Rating for Healthpeak Properties (DOC)
UBS analyst Michael Goldsmith maintained a Hold rating on Healthpeak Properties today and set a price target of $21.50.
55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Goldsmith is a 4-star analyst with an average return of 7.2% and a 66.26% success rate. Goldsmith covers the Real Estate sector, focusing on stocks such as Mid-America Apartment, Healthpeak Properties, and Healthcare Realty Trust.
In addition to UBS, Healthpeak Properties also received a Hold from Barclays’s Richard Hightower in a report issued yesterday. However, on July 6, Mizuho Securities maintained a Buy rating on Healthpeak Properties (NYSE: DOC).
Based on Healthpeak Properties’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $752.95 million and a net profit of $193.63 million. In comparison, last year the company earned a revenue of $702.89 million and had a net profit of $42.83 million
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DOC in relation to earlier this year. Most recently, in May 2026, Scott R Bohn, the CDO and Head of Lab of DOC sold 10,989.00 shares for a total of $213,736.05.
Read More on DOC:
Disclaimer & DisclosureReport an Issue
- Healthpeak Properties price target raised to $21.50 from $19 at UBS
- Healthpeak Properties initiated with an Equal Weight at Barclays
- Healthpeak Properties price target raised to $24 from $21 at Mizuho
- Healthpeak Properties price target raised to $21 from $18 at JPMorgan
- Healthpeak Properties resumed with a Market Perform at Raymond James
